The latest research on stem cell therapy for ALS and motor neuron disease. How MSC treatment may slow progression, protect motor neurons, and improve quality of life for ALS patients.
ALS (amyotrophic lateral sclerosis) kills upper and lower motor neurons through a cascade involving protein aggregation (TDP-43, SOD1 misfolding), glutamate excitotoxicity, mitochondrial dysfunction, and neuroinflammation. MSC therapy targets the neuroinflammatory component: MSCs suppress microglial activation, reduce TNF-α and IL-1β production, and release neurotrophic factors (BDNF, GDNF, VEGF) that support surviving motor neurons. Intrathecal delivery achieves direct CSF contact with lumbar motor neuron pools.
Phase I/II trials (Mazzini et al. 2003–2015, BrainStorm Cell Therapeutics NurOwn trials) established safety and showed slowing of ALSFRS-R decline in early-stage patients. Responder analyses indicate that fast-progressors (ALSFRS-R decline >1 point/month) and patients treated within 24 months of diagnosis show the most benefit. MSC therapy is not a cure for ALS but functions as a neuroprotective intervention that may extend the period of functional independence.
Best candidates: confirmed ALS diagnosis (excluding mimics), relatively preserved respiratory function (FVC >50%), within 36 months of symptom onset, and stable enough to travel. Our team conducts detailed pre-treatment eligibility assessment including neurological evaluation, pulmonary function testing, and review of genetic status (SOD1, C9orf72). Realistic expectations and shared decision-making are central to our consultation process.
Related articles: Stem Cell Therapy for Spinal Cord Injury (2026 Guide) | Stem Cell Therapy for Cerebral Palsy (2026 Guide) | Understanding Stem Cell Therapy (2026 Complete Guide) | Is Stem Cell Therapy Safe? Understanding Risks, Benefits & Evidence
Related treatments: Multiple Sclerosis Stem Cell Therapy | Dementia Stem Cell Therapy | Chronic Pain Stem Cell Therapy